Search results for "Combined Modality Therapy"

showing 10 items of 376 documents

Future perspectives in hepatocellular carcinoma.

2010

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. Due to late diagnosis and advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefits have been available in up to 70% of patients. However, major progress has been achieved with regard to surveillance, early diagnosis, and multimodal treatment approaches during the last years leading to an improvement in prognosis. Particularly, the increasing knowledge of molecular hepatocarcinogenesis today provides the opportunity for targeted therapy. The multikinase inhibitor sorafenib has broadened the therapeutic horizon for patients with advanced disease and is current…

SorafenibOncologyAblation Techniquesmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationGastroenterologyTargeted therapyInternal medicinemedicineAdjuvant therapyCombined Modality TherapyHumansChemoembolization TherapeuticPrecision MedicineTranscatheter arterial chemoembolizationProtein Kinase InhibitorsHepatologybusiness.industryLiver NeoplasmsGastroenterologymedicine.diseaseCombined Modality TherapyFibrosisLiver TransplantationHepatocellular carcinomaPersonalized medicinebusinessmedicine.drugForecastingDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Recurrence of hepatocellular carcinoma after liver transplantation: an update.

2015

Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70–85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. Th…

SorafenibOncologyCancer Researchmedicine.medical_specialtyrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentliving donorLiver transplantationMilan criteriaGastroenterologyLeukocyte CountRisk FactorsInternal medicinemedicineBiomarkers TumorCombined Modality TherapyHumansalpha-FetoproteinPerioperative PeriodSurvival rateimmunosuppressionbusiness.industryRisk FactorLiver NeoplasmsImmunosuppressionGeneral MedicinePerioperativehepatocellular carcinomamedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationTumor BurdenOncologyLiver NeoplasmHepatocellular carcinomaalpha-FetoproteinsNeoplasm Recurrence Localbusinessmedicine.drugHumanFuture oncology (London, England)
researchProduct

Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

2015

According to the guidelines of the European Association for the Study of the Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clinic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in five stages (0, A, B, C and D) on the basis of a number of prognostic and treatment- related variables such as tumor status and liver function. A specific treat ment approach is then proposed for each of the above-mentioned stages. Transarterial chemoembolization (TACE) is recommended as first-line therapy in the treatment of patients with intermediate-stage (BCLC-B class) HCC [1]. The efficacy of this procedure…

SorafenibOncologyNiacinamideCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCombination therapyHCC; TACE; combination therapy; intermediate stage; sorafenibAntineoplastic Agentscombination therapyInternal medicineMedicineHumansStage (cooking)Chemoembolization TherapeuticHCCProtein Kinase InhibitorsTACEintermediate stagePerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsGeneral Medicinemedicine.diseaseCombined Modality Therapydigestive system diseasesPortal vein thrombosisSurgeryOncologyHepatocellular carcinomasorafenibLiver functionbusinessLiver cancermedicine.drug
researchProduct

Surgical treatment of solitary sternal metastasis from breast cancer Case report

2016

Bone metastasis is a frequent and early complication of breast cancer. This case report describes a technique for a partial exeresis of the sternum and the reconstruction of the pleura with autologous dermis from the lower abdomen and the loss of substance with a myocutaneous flap.We describe the case of a 50-year old woman with a sternal excavated lesion with pathologic fracture due to an invasive adenocarcinoma, treated with a partial exeresis of the sternum and the reconstruction with a myocutaneous flap.The patient doesn't show evidence of recurrent disease and the stability of her chest well preserved.Metastatic breast cancer to the sternum, if detected early and treated aggressively, …

SternumSettore MED/21 - Chirurgia ToracicaCytarabineBreast cancer Sternal metastasis SternectomyBone NeoplasmsBreast NeoplasmsAdenocarcinomaMiddle AgedCombined Modality TherapyMyocutaneous FlapSettore MED/18 - Chirurgia GeneraleFractures SpontaneousAntineoplastic Combined Chemotherapy ProtocolsHumansPleuraFemaleCyclophosphamideEpirubicin
researchProduct

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct

Integrated treatment of first episode psychosis with online training (e-learning): study protocol for a randomised controlled trial

2014

Background: The integrated treatment of first episode psychosis has been shown to improve functionality and negative symptoms in previous studies. In this paper, we describe a study of integrated treatment (individual psychoeducation complementary to pharmacotherapy) versus treatment as usual, comparing results at baseline with those at 6-month re-assessment (at the end of the study) for these patients, and online training of professionals to provide this complementary treatment, with the following objectives: 1) to compare the efficacy of individual psychoeducation as add-on treatment versus treatment as usual in improving psychotic and mood symptoms; 2) to compare adherence to medication,…

Time Factorsmedicine.medical_treatmentGlobal Assessment of FunctioningMedicine (miscellaneous)Liebowitz social anxiety scaleWeb-based instructionlaw.inventionStudy Protocolmulticenter trialClinical ProtocolsRandomized controlled triallawSurveys and QuestionnairesSingle-Blind MethodPharmacology (medical)PHARMACOLOGY (MEDICAL)validationPositive and Negative Syndrome ScaleCombined Modality TherapyTreatment OutcomeResearch Designspanish versionAprenentatge electrònicAnxietymedicine.symptomAntipsychotic Agentsmedicine.medical_specialtyPsicosiMedication Adherencescale1st-episode psychosisPredictive Value of TestsPsychoeducationmedicineHumansSocial BehaviorPsychiatryPsychiatric Status Rating ScalesInternetbusiness.industryMEDICINEBrain-Derived Neurotrophic FactorHamilton Rating Scale for DepressionPsychoses5-year follow-upstandard treatementPsychotherapyAffectLogistic ModelsMoodPsychotic Disordersopus trialSpainquality-of-lifeLinear ModelsQuality of Lifebusinesscognitive-behavior therapyBiomarkersComputer-Assisted InstructionTrials
researchProduct

Endoscopic management of a case of 'complete septate uterus with unilateral haematometra'

1995

Endoscopy and ultrasound was used to diagnose a 13 year old virgin girl who presented with dysmenorrhoea and suspected right side adnexal tumescence. The girl was found to have a complete septate uterus with non-communicating right hemicavity and haematometra, an exceptional type of Mullerian anomaly. After pretreatment with buserelin, hysteroscopic metroplasty was successfully performed.

medicine.medical_specialtyAdolescentUterusHysteroscopyBuserelinDysmenorrheaHematometraMedicineHumansUltrasonographyHematometraTumescencemedicine.diagnostic_testbusiness.industryRehabilitationUterusObstetrics and Gynecologymedicine.diseaseCombined Modality TherapyBuserelinEndoscopySurgerymedicine.anatomical_structureTreatment OutcomeReproductive MedicineHysteroscopyFemalebusinessHaematometraSeptate uterusmedicine.drug
researchProduct

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

2020

International audience; Background: Several guidelines dedicated to metastatic colorectal cancer (mCRC) are available. Since 2013 no recent guidelines are specifically dedicated to older patients and based on a systematic review. Materials and methods: A multidisciplinary Task Force with digestive oncologists, geriatricians and methodologists from the SoFOG was formed in 2016 to update recommendations on medical treatment of mCRC based on a systematic review of publications from 2000 to 2018. Search strategy has followed a standardized protocol from the formulation of clinical questions and definition of a search algorithm to the selection of complete articles for recommendations. Results: …

medicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Context (language use)Targeted therapyMetastasisMetastasisTargeted therapy03 medical and health scienceschemistry.chemical_compoundOlder patient0302 clinical medicineRegorafenibMedicineHumansChemotherapyNeoplasm MetastasisIntensive care medicineSocieties MedicalAgedNeoplasm StagingHepatologyPerformance statusbusiness.industryGastroenterologymedicine.diseaseCombined Modality TherapyColorectal cancer3. Good healthGeriatric oncologychemistry030220 oncology & carcinogenesisQuality of Life030211 gastroenterology & hepatologyFrancebusinessColorectal Neoplasmsmedicine.drug
researchProduct

Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp (Ctenopharyngodon idella) fed a high-fat diet

2008

We investigated whether the hypolipidaemic effect of fenofibrate and fasting observed in most omnivorous mammals may also apply to herbivorous fish. Grass carp (Ctenopharyngodon idella) fed a high-fat (8 %) diet exhibited a marked increase in blood lipids and body fat after 6 weeks. They were then treated with fenofibrate (100 mg/kg body weight) in the same high-fat diet for 2 weeks, followed by fasting for 1 week. Plasma lipid concentration, body fat amount, fatty acid composition, plasma thiobarbituric acid-reactive substances and some parameters related to hepatic fatty acid oxidation were measured, and liver samples were stained for histological examination. Fenofibrate treatment decrea…

medicine.medical_specialtyCarpsmedicine.drug_classMedicine (miscellaneous)Blood lipidsHyperlipidemiasFibrateBiologyThiobarbituric Acid Reactive SubstancesLipid peroxidationFish Diseaseschemistry.chemical_compoundFenofibrateInternal medicinemedicineAnimalsBeta oxidationHypolipidemic AgentsNutrition and DieteticsFenofibrateCholesterolFatty AcidsLipid metabolismFastingLipid Metabolismbiology.organism_classificationCombined Modality TherapyDietary FatsGrass carpEndocrinologyLiverchemistryAnimal Nutritional Physiological Phenomenalipids (amino acids peptides and proteins)Lipid PeroxidationOxidation-Reductionmedicine.drugBritish Journal of Nutrition
researchProduct

Prognostic factors in the treatment of Ewing's sarcoma

1987

From 1981 up to February 1985, a total of 93 protocol patients entered the study CESS 81. The protocol recommended an initial 18-week period of polychemotherapy (VACA) followed by local therapy and two additional cycles of chemotherapy. Local therapy consisted either of radical surgery or of incomplete resection plus postoperative irradiation with 36 Gy or of radiotherapy alone (46 and 60 Gy). Centrally located lesions were always irradiated with 60 Gy. This article summarizes the data after 5 years. Data of 93 patients were analysed in October 1986 after a median follow-up of 37 months. The projected 5-year survival is 50%. The relapse rate was 42%, distant relapses occurred in 19%, local …

medicine.medical_specialtyChemotherapybusiness.industryPaediatric oncologymedicine.medical_treatmentPostoperative irradiationEwing's sarcomaHematologymedicine.diseaseSurgeryRadiation therapyOncologyMedicineCombined Modality TherapyRadiology Nuclear Medicine and imagingSarcomaRadical surgerybusinessRadiotherapy and Oncology
researchProduct